Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-361-3p mimic
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
miR-361-3p mimic is an experimental **microRNA replacement therapeutic** consisting of a synthetic oligonucleotide designed to restore or augment the tumor-suppressive activity of endogenous miR-361-3p. In the provided publication context, it is used as a research-stage agent in prostate cancer models, where increased miR-361-3p suppresses malignant phenotypes including proliferation, migration, and invasion. The reported biology indicates that its antitumor effects are mediated at least in part through repression of **GLI family zinc finger 1** and downstream attenuation of **AKT/mTOR signaling**. No specific commercial developer, manufacturer, clinical product identity, branded formulation, or clinical-stage development program is clearly established from the provided evidence.
- Other names
- miR-361-3p mimicmiR361-3p mimicmiR 361-3p mimicmicroRNA-361-3p mimicmicroRNA361-3p mimicmicroRNA 361-3p mimicmiRNA-361-3p mimicmiRNA361-3p mimicmiRNA 361-3p mimic
02
Targets
SH2B1 (SH2B adapter protein 1)GLI family zinc finger 3 (GLI3) mRNAGLI1
Beyond the preview
Go deeper on miR-361-3p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-361-3p mimic.